InsidersTradesSigma
Follow the OTOFARMA OTOFARMA: THE BOARD OF DIRECTORS APPROVES THE DRAFT FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025, REVISED THE FINANCIAL CALENDAR AND CALLS THE SHAREHOLDERS' MEETING FOR JUNE 29, 2026 (FIRST CALL) share price and the full management transaction log of the company, a listed issuer based in Italy. Shares are quoted on IT IT, under the oversight of Consob. Market capitalisation: €16.7m. The latest transaction was filed on 28 May 2026 (Other). Among the most active insiders: Anonymous (PDMR). Every trade is accessible without an account.
Analysts rate OTOFARMA OTOFARMA: THE BOARD OF DIRECTORS APPROVES THE DRAFT FINANCIAL STATEMENTS AND CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025, REVISED THE FINANCIAL CALENDAR AND CALLS THE SHAREHOLDERS' MEETING FOR JUNE 29, 2026 (FIRST CALL) Strong Buy (bullish), based on 1 analysts. Average price target: €5.40.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
OTOFARMA announced that the board of directors approved the financial statements and consolidated financial statements as of December 31, 2025. The company also revised its financial calendar and called the shareholders' meeting for June 29, 2026 (first call).